CDI Laboratory Develops Promising New Antibiotic for Resistant Gonorrhea
Hackensack Meridian HealthJSF-2659, developed to be administered orally, could be a game changer in treating Neisseria gonorrhoeae, which is on the World Health Organization’s global list of “priority pathogens” for its resistance to existing drugs.